» Articles » PMID: 6344979

An Autopsy Study of Histologic Progression in Non-Hodgkin's Lymphomas. 192 Cases from the National Cancer Institute

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 1983 Aug 1
PMID 6344979
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Histologic slides were reviewed from 192 autopsies of patients with non-Hodgkin's lymphomas admitted to the National Cancer Institute (NCI) from 1953 to 1975. Each autopsy was classified according to the systems of Rappaport and Lukes-Collins. Comparisons with the initial diagnosis were made. The initial histologic diagnoses of the autopsied population were similar in distribution to other published series of non-Hodgkin's lymphomas. Of the 56 cases which initially demonstrated nodular patterns of growth, the following distribution was found at autopsy: 25%, no lymphoma; 6%, nodular lymphoma; 32%, diffuse histiocytic (large cell) lymphoma (DHL); 21%, diffuse undifferentiated (non-Burkitt's) lymphoma (DUL); and 16%, the remaining diffuse morphologies. Of the 136 patients with initial diagnosis of diffuse lymphoma, the following distributions were observed at autopsy: 20%, no lymphoma; 0%, nodular lymphoma; 31%, diffuse histiocytic (large cell) lymphoma; 12%, diffuse undifferentiated (non-Burkitt's) lymphoma; 9%, Burkitt's tumor; 14%, diffuse poorly differentiated lymphocytic lymphoma; and 14%, the remaining diffuse morphologic types. One hundred and thirty-four cases which were initially diagnosed as follicular center cell type within the Lukes-Collins classification gave the following distribution at autopsy: 21%, no lymphoma; 25%, small noncleaved type; 17%, large noncleaved type; 23%, non-follicular center cell lymphomas (17% immunoblastic B); and the remaining 13% were distributed among the other follicular center cell types. This autopsy review demonstrates the rarity of nodular (follicular) lymphomas at autopsy, and the predominance of the diffuse histiocytic or "transformed" type. This study provides a comparison of the rate of histologic progression of lymphomas in the same patient population at autopsy with a previously published study of progression during life.

Citing Articles

Long-term remission following CAR-T therapy in a patient with transformed follicular lymphoma relapse after allogeneic stem cell transplantation.

Kubo R, Onodera K, Onishi Y, Fukuhara N, Harigae H Ann Hematol. 2024; 104(1):841-845.

PMID: 39738826 DOI: 10.1007/s00277-024-06150-8.


Clinical-Demographic Profile, Prognostic Factors and Outcomes in Classic Follicular Lymphoma Stratified by Staging and Tumor Burden: Real-World Evidence from a Large Latin American Cohort.

Nogueira D, Lage L, Reichert C, Culler H, de Freitas F, Mendes J Cancers (Basel). 2024; 16(23).

PMID: 39682103 PMC: 11640734. DOI: 10.3390/cancers16233914.


Significance of initial, interim and end-of-therapy F-FDG PET/CT for predicting transformation risk in follicular lymphoma.

Xie M, Wang L, Jiang Q, Luo X, Zhao X, Li X Cancer Cell Int. 2021; 21(1):394.

PMID: 34311728 PMC: 8314559. DOI: 10.1186/s12935-021-02094-5.


Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry.

Provencio M, Sabin P, Gomez-Codina J, Torrente M, Calvo V, Llanos M PLoS One. 2017; 12(5):e0177204.

PMID: 28493986 PMC: 5426713. DOI: 10.1371/journal.pone.0177204.


BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma.

Correia C, Schneider P, Dai H, Dogan A, Maurer M, Church A Blood. 2014; 125(4):658-67.

PMID: 25452615 PMC: 4304111. DOI: 10.1182/blood-2014-04-571786.